iX Biopharma Ltd. (SGX: 42C)

Market Cap	21.20M
Revenue (ttm)	5.96M
Net Income (ttm)	-10.79M
Shares Out	883.34M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,600
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0220 - 0.0600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 4, 2025

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 42
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 42C

Financial Performance

In 2024, iX Biopharma's revenue was 5.96 million, an increase of 0.78% compared to the previous year's 5.91 million. Losses were -10.79 million, 12.3% more than in 2023.